Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modernizing the NCI60 Cell Line Screen for Phenotypic Drug Discovery in the 21st Century.

Cancer research - 1 Aug 2024

Colombo Gianna M, Corsello Steven M

Abstract excerpt

Over the past three decades, high-throughput phenotypic cancer cell line screens have revealed unanticipated small-molecule activities and illuminated connections between tumor genotypes and anticancer efficacy. Founded in 1984, the National Cancer Institute's "NCI60" screen laid the conceptual groundwork for the contemporary landscape of phenotypic drug discovery. NCI60 first operated as a primary bioactivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Screening Assays, Antitumor

Share to High-Throughput Screening Assays

Share to Neoplasms

Share to United States

Source

Identifiers

PMID: 39086314
DOI: 10.1158/0008-5472.CAN-24-1506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modernizing the NCI60 Cell Line Screen for Phenotypic Drug Discovery in the 21st Century.PMID 39086314Read ↗

Challenges and the Advancement in High-Throughput Screening Strategies for Cancer TherapeuticsSemantic proximity Read ↗

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.Semantic proximity Read ↗

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.Semantic proximity Read ↗

An information-intensive approach to the molecular pharmacology of cancer.Semantic proximity Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cellsSemantic proximity Read ↗

rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in RSemantic proximity Read ↗

Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling dataSemantic proximity Read ↗

Phenotypic screening in cancer drug discovery - past, present and future.Semantic proximity Read ↗

MACE: mutation-oriented profiling of chemical response and gene expression in cancers.Semantic proximity Read ↗

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experimentsSemantic proximity Read ↗

Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.